Research programme: anti-HIV agents - Quigley Pharma
Alternative Names: QR 437Latest Information Update: 16 Jul 2016
At a glance
- Originator Quigley Pharma
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in HIV-infections(Prevention) in USA
- 16 Jul 2009 Preclinical trials in HIV infections in USA (unspecified route)
- 02 Feb 2005 Preclinical trials in HIV infections prevention in USA (unspecified route)